Registered Members Login:
   
Forgotten Your Details? Click Here To Recover +
Welcome To The ShareCafe Community - Talk Shares And Take Stock With Smart Investors - New Here? Click To Register >


scipio79
Posted on: Apr 27 2020, 09:35 PM


Group: Member
Posts: 77

It would explain the heart related concerns by the FDA that we all were wondering about many months ago.
  Forum: By Share Code

scipio79
Posted on: Feb 14 2020, 01:20 AM


Group: Member
Posts: 77

I know, but hope springs eternal.
  Forum: By Share Code

scipio79
Posted on: Feb 14 2020, 12:05 AM


Group: Member
Posts: 77

A spring roll out is a win in my book. Let's hope that occurs because if it does our stock will be worth 2x by year's end.
  Forum: By Share Code

scipio79
Posted on: Jan 13 2020, 12:49 PM


Group: Member
Posts: 77

"First US sales are expected in 2H21." Certainly, this is a typo and the author of the article means 2H20, right?

EDIT: Sorry, Waz beat me to it.
  Forum: By Share Code

scipio79
Posted on: Dec 12 2019, 12:56 PM


Group: Member
Posts: 77

Per uhohinc on his google page:

December 10, 2019........There were 43,000 shares of Clvly available to shortsale on December 10.....The person whom contacted me was interested to inquire if I was a long term holder of Clinuvel, and if I was interested in contracting my CLVLY out for shortsellers. In USA CLVLY is only available on the USA shortselling market, I was informed.

I asked where can I see the site where the shortsales of Clvly are so I can view and follow....no straight answer.

I asked how much would get for “loaning” my shares for a shortseller, no straight answer, but dependent on demand the percent or cost to shortseller can go as high as %15 for which broker gets their graduated increasing share first. Atypically it does not reach %15 and is closer to 1% to owner of shares.

-----------------------------

I bet LH2 sold out and loaned his shares. Then he went negative trying to talk the stock down. Some good news would remedy this manipulation attempt. Great news would cause one heck of a squeeze.
  Forum: By Share Code

scipio79
Posted on: Dec 3 2019, 08:10 AM


Group: Member
Posts: 77

Keep talking it down. I bought more at a discount i didn't think I'd see post approval.

Edit: Not directed to you Dr. Wally.
  Forum: By Share Code

scipio79
Posted on: Dec 3 2019, 01:12 AM


Group: Member
Posts: 77

Some of the long term holders on here sold. Any really large holders selling would be public knowledge, or will be at the end of the quarter. Not a big deal, yet.
  Forum: By Share Code

scipio79
Posted on: Dec 1 2019, 12:21 AM


Group: Member
Posts: 77

Agreed Sharelooker. The EPP indication for Scenesse was merely a drug in search of a disease to get the FDA stamp of approval. Don't misunderstand, I am very happy for EPP sufferers who can now enjoy the daylight. However, Clinuvel has bigger plans. Now that FDA approval has occurred, it's time to roll out what this company really has planned. I highly doubt the 7.5 billion market cap target was pulled out of thin air either. It was chosen as a realistic and achievable target for what the company has planned for the future. It is now time for PW to show he can execute his plan for the growth of Clinuvel. 7.5 billion market cap is about $140 USD a share for CLVLY. I'll take that as a good 20 year investment. LH, I'm glad you are looking out for possible threats in the environment, but I believe you have given the MT threat more credence than necessary. Once winter is over, the real fun begins for us all. PW: don't screw up the US roll out! I expect double the revenue in one year and a $45 USD stock price. Make it so.
  Forum: By Share Code

scipio79
Posted on: Nov 28 2019, 11:17 PM


Group: Member
Posts: 77

Levelheaded on Nov 20: I bought some over the last few days, but I will be accelerating my buys now. The price is way too low and the potential way too high. The price is too low even just for EPP.

Levelheaded on Nov 22: I will not lie since the AGM I have done a lot of soul searching and I am more bearish than I have ever been. I hope the management team can deliver and deliver on time. Clinuvel needs some positive news.

What changed? Where are the positives of the SWOT analysis you promised? You have been a great contributor over the years, but the sudden and unfounded apocalyptic view of this company is confounding. One could say you are trying to get cheap shares considering the limited number of shareholders (only 4200) and the sway this board has on some retail investors. A slight change in sentiment can have a drastic effect on the share price. You went extremely bearish a mere 48 hours after claiming you were buying more and that the price was too low. More far fetched conspiracies have been offered here.

The winter doldrums are here as they are every year with this company until we get sales in the southern hemisphere. Clinuvel needs to hit the ground running in the US come March. However the single best thing clinuvel could do to help the share price is a little PR and expand the shareholder base. Nasdaq would be one way to do that. More institutional investment would be good too. Many promising bios in the US have institutional investment of 50% or more. While clinuvel could be a little more agressive, I am willing to cut them some slack considering the hurdles overcome since the epitan days. However, its time to execute and open that US piggybank.
  Forum: By Share Code

scipio79
Posted on: Nov 27 2019, 11:07 AM


Group: Member
Posts: 77

This is not surprising for a new molecule. The FDA is simply doing its due diligence to keep U.S citizens safe, its raison d'être. But as we know (thanks Dr. Wally!), the safety profile of our drug is outstanding. It still does not tie the hands of doctors regarding their prescribing decisions.

As for the recent melancholy because the stock price has stalled and retreated, remember from where we came and where we're going. Rome was not built in a day, as the saying goes. My percentages since my first investment 15 years ago, even with all the subsequent buys bringing my average up, bear that out. Take a look at your percentages and get some perspective. We've done OK so far.
Attached thumbnail(s)
Attached Image


 
  Forum: By Share Code

scipio79
Posted on: Nov 27 2019, 10:04 AM


Group: Member
Posts: 77

Great discussion as always, gentlemen.

A brief response to this statement: "For all we know, the FDA may have directed the post-authorization studies Clinuvel is using and won't want any off label use until DNA repair is proven."

The US FDA cannot control off label use of an otherwise approved drug. Scenesse has no "black box" warning that I am aware of, thus a doctor has First Amendment freedom to prescribe a drug as she/he deems medically appropriate.
  Forum: By Share Code

scipio79
Posted on: Nov 20 2019, 12:07 PM


Group: Member
Posts: 77

Yes, like a vaccine against uv induced skin cancer that must be reapplied over and over, with bonus dna repairing qualities. $€£¥
  Forum: By Share Code

scipio79
Posted on: Nov 20 2019, 11:38 AM


Group: Member
Posts: 77

I remember Uhohinc posting about it over the years. The further confirmation, and more PR, would be useful
  Forum: By Share Code

scipio79
Posted on: Nov 20 2019, 10:30 AM


Group: Member
Posts: 77

If Clinuvel's tests prove this out over the next year or so, we're all very rich. And not retire early rich but trust fund for generations rich!
Attached thumbnail(s)
Attached Image


 
  Forum: By Share Code

scipio79
Posted on: Nov 20 2019, 10:00 AM


Group: Member
Posts: 77

Lotions? When?!
Attached thumbnail(s)
Attached Image



 
  Forum: By Share Code

scipio79
Posted on: Nov 18 2019, 06:40 AM


Group: Member
Posts: 77

Why indeed. That was my reaction too. Why tie your hands like that without need. I hope someone asks that question to management.
  Forum: By Share Code

scipio79
Posted on: Nov 17 2019, 11:53 PM


Group: Member
Posts: 77

My understanding from a quick google search is that the US patent for vitiligo is good for 20 years from filing: https://www.uspto.gov/web/offices/pac/mpep/s2701.html

The patent was filed in 2013 according to the USPTO: http://patft.uspto.gov/netacgi/nph-Parser?...esse+AND+wolgen
  Forum: By Share Code

scipio79
Posted on: Nov 13 2019, 11:19 AM


Group: Member
Posts: 77

Thanks PADerm. TD Ameritrade gave me the runaround today. Your emails from them are helpful.
  Forum: By Share Code

scipio79
Posted on: Oct 31 2019, 10:54 AM


Group: Member
Posts: 77

https://www.businesswire.com/news/home/2019...bRdYOj2VdwnuKwa

ER Out
  Forum: By Share Code

scipio79
Posted on: Oct 27 2019, 04:17 AM


Group: Member
Posts: 77

https://www.gurufocus.com/news/852810/2-bio...-joseph-edelman

I'll end with this article. One well known hedge funder is heavily invested in FOMX and he picks winners. Thanks for your thoughts PADerm.
  Forum: By Share Code

scipio79
Posted on: Oct 26 2019, 09:40 PM


Group: Member
Posts: 77

I know we are here to discuss CUV, but every now and then someone throws out other investment opportunities, like Avita, which I thank you for as I’m up 100% on that one. Anyway, yesterday, I stumbled across another such opportunity I want to share with you all and get your feedback. The company is Foamix Pharma (FOMX Nasdaq) and just got FDA approval for a topical Minocycline, the only one on market. Many dermatologists are excited about this as they can treat acne effectively and safely without the systemic effects a pill has on the body. (PADerm, what do you think?) Foamix has also submitted an NDA for a topical rosacea treatment and other products in the pipeline where they use their proprietary delivery of topical therapies. https://www.foamix.com/products-pipeline Price targets are at 11 to 30 USD and current price is 2.71 USD. As with CUV, shorters have attacked this stock after approval. FOMX is 62% owned by institutions and mutual funds included several large funds. While they are funded to roll out manufacturing on their own, there are talks that the company is a take over opportunity. They could also control the acne minocycline market and be very profitable in a large and perpetual market as early as next year. As with CUV, FOMX is not heavily diluted, only 61 million shares issued and about 20 million float. Unlike CUV, FOMX is not yet profitable. Some of the large institutions have average buy-ins of around 5 USD. I think this could likely be a 5 bagger+. Thoughts? As a disclaimer, I do not own the stock but will likely buy a decent sized position this coming week.
  Forum: By Share Code

scipio79
Posted on: Oct 24 2019, 09:38 AM


Group: Member
Posts: 77

It never fails. I transfer money to my broker to buy more, and before the money clears, CUV takes off! I should tranfers a little every day with intent to buy!
  Forum: By Share Code

scipio79
Posted on: Oct 16 2019, 08:14 PM


Group: Member
Posts: 77

In other words, this thing is a money printer. Hold on to your hats (and your shares), fellas.
  Forum: By Share Code

scipio79
Posted on: Oct 12 2019, 07:34 AM


Group: Member
Posts: 77

1 bn USD in revenue is about $500 USD in share price at a 20 PE, if my math is not crap. I'll take that!
  Forum: By Share Code

scipio79
Posted on: Oct 11 2019, 10:09 PM


Group: Member
Posts: 77

I wish I had that many PADerm but I'm glad to know I'm in the top 200 holders. Yeah, with that kind of share distribution, no takeover of any kind is happening unless we want it to.
  Forum: By Share Code

scipio79
Posted on: Oct 11 2019, 05:03 AM


Group: Member
Posts: 77

From Bloomberg: https://www.bloomberg.com/news/articles/201...a-drug-approval Notice the part I underlined.


Clinuvel Pharmaceuticals Ltd. surged the most in five years after the U.S. Food and Drug Administration approved its treatment for a rare skin disorder that causes sensitivity to light.

Shares of the Melbourne-based bio-pharmaceutical firm jumped as much as 57% in Sydney, the most since October 2014, after the U.S. allowed the use of the drug Scenesse to treat erythropoietic protoporphyria. Clinuvel rose to a record high of A$44.39, valuing the company at A$2.2 billion ($1.5 billion).

Clinuvel shares skyrocket after FDA approval of Scenesse. Erythropoietic protoporphyria induces skin damage from exposure to light, forcing patients to “lead an indoor or nocturnal existence,” Clinuvel said in a release. Scenesse treats the genetic disorder by increasing the skin’s levels of melanin and blocking ultraviolet radiation and sunlight, according to the company’s website.

Scenesse is the first FDA-approved treatment to help erythropoietic protoporphyria patients increase their exposure to light, the agency said. The drug was approved for use in Europe in December 2014.

Clinuvel intends to distribute Scenesse directly to U.S. hospitals within 12 months, Chief Executive Officer Dr. Philippe Wolgen said in a phone interview. The company also plans to sell the drug at the same price worldwide.

A single price-point “is quite alien to our industry,” Wolgen said. “We wanted to show the American payers that they would not be paying more for a pharmaceutical product than the Europeans and the Swiss do.”

(Update with share price, comments from company)
  Forum: By Share Code

scipio79
Posted on: Oct 11 2019, 12:21 AM


Group: Member
Posts: 77

I disagree. The EMA placed restrictions on distribution of the product. The FDA placed no such restriction. It merely ordered a study of cardiac repolarization which only lasts 10 months. The longitudinal study is required for a decade, but only requires reporting of adverse events. This is a mere administrative requirement that can be easily and cheaply done. As a brand new molecule, these requirements are not draconian, but prudent and will establish, hopefully, the long term safety of the drug. The timelines were suggested by Clinuvel. I still see no barrier to US doctors prescribing this drug as they see fit. The only barrier to that is Clinuvel itself.
  Forum: By Share Code

scipio79
Posted on: Oct 10 2019, 11:48 PM


Group: Member
Posts: 77

This seems like a big deal:

REQUIRED PEDIATRIC ASSESSMENTS
Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for
new active ingredients (which includes new salts and new fixed combinations), new
indications, new dosage forms, new dosing regimens, or new routes of administration
are required to contain an assessment of the safety and effectiveness of the product for
the claimed indication in pediatric patients unless this requirement is waived, deferred,
or inapplicable.

Because this drug product for this indication has an orphan drug designation, you are
exempt from this requirement.
  Forum: By Share Code

scipio79
Posted on: Oct 10 2019, 11:46 PM


Group: Member
Posts: 77

Just for you Dr. Wally:

ADVISORY COMMITTEE
Your application for Scenesse was not referred to an FDA advisory committee because
the application did not raise significant safety or efficacy issues in the intended
population.
  Forum: By Share Code

scipio79
Posted on: Oct 9 2019, 11:20 PM


Group: Member
Posts: 77

CLVLY pre market per TD Ameritrade


Attached thumbnail(s)
Attached Image


 
  Forum: By Share Code

scipio79
Posted on: Oct 9 2019, 05:10 AM


Group: Member
Posts: 77

If a private payer can find a doctor to prescribe it for, say, cancer prevention, for a fair skinned actress, such is OK under US law.
  Forum: By Share Code

scipio79
Posted on: Oct 9 2019, 04:11 AM


Group: Member
Posts: 77

It will pay off in the end, he said. And he will be right.
Attached image(s)
Attached Image

 
  Forum: By Share Code

scipio79
Posted on: Oct 9 2019, 03:58 AM


Group: Member
Posts: 77

I was curious of the exact date of my first purchase. Here it is: 09/29/2004 11:13:54 Bought 2025 EPTNF @ 0.64
  Forum: By Share Code

scipio79
Posted on: Oct 9 2019, 03:47 AM


Group: Member
Posts: 77

That's America and the First Amendment for you! Congrats to all. Doctors in the US can prescribed this drug for any reason they fell appropriate!!
  Forum: By Share Code

scipio79
Posted on: Oct 3 2019, 09:13 AM


Group: Member
Posts: 77

I have been in this stock since the Epitan days in 2005. Over the years I have accumulated more shares and have a significant amount considering I starting accumulating as a poor university student. Many of you have significantly more shares. I have been encouraged by the research and thoughts shared here, and you have helped me keep the faith through the hard times. However, some of you have recently become spineless, whiny children. We entered this thing as a penny stock because we saw potential. We have made some money. We are on the verge of FDA approval (Yes, I believe it will happen Tuesday) and too many of you are losing your nerve. I hope you understand what FDA approval means. It means that while Clinuvel can only market the drug for approved applications, doctors in the USA can prescribed it for any reason. More importantly, however, it means that Clinuvel can feel unchained to communicate about other aspects of its pipeline, including the OTC products, without worrying about the FDA. If Clinuvel has developed an OTC sun block cream that can prevent you from getting skin cancer, that is a game changer. If it has done that, or does so in the future, our great-great-great grandchildren will not need to work. We will all be fabulously wealthy. No risk, no reward gentlemen(and ladies!). Strap in and hang on. Win or lose, I've been waiting for this for nearly 15 years. Stand fast, we are almost there. Attached Image
  Forum: By Share Code

scipio79
Posted on: Sep 1 2019, 11:28 PM


Group: Member
Posts: 77

Yes, that's a big deal:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2945483/
  Forum: By Share Code

scipio79
Posted on: Aug 20 2019, 12:14 AM


Group: Member
Posts: 77

I hope you all are right and we have seen the bottom. Picked up a few more ADR shares at $16.99.
  Forum: By Share Code

scipio79
Posted on: Aug 18 2019, 07:30 AM


Group: Member
Posts: 77

A little off subject, but have any of you invested in a company focusing on the microbiome, essentially gut health? I'm looking at a few companies and would like to get input from this savvy group of investors. Thanks.
  Forum: By Share Code

scipio79
Posted on: May 16 2019, 03:03 AM


Group: Member
Posts: 77

I bought in to Avita (AVMXY) today. Been thinking about it for several months. I wish I had been more deliberative.
  Forum: By Share Code

scipio79
Posted on: May 10 2019, 05:30 AM


Group: Member
Posts: 77

I just watched 37000 shares of clvly get purchased. Late in the week buy up???
Attached thumbnail(s)
Attached Image


 
  Forum: By Share Code

scipio79
Posted on: May 3 2019, 08:04 PM


Group: Member
Posts: 77

Speaking of Evonik
Attached thumbnail(s)
Attached Image


 
  Forum: By Share Code

scipio79
Posted on: May 3 2019, 06:44 AM


Group: Member
Posts: 77

I imagine a lawyer said such a statement would be prudent considering Stan's wildly optimistic letter. Don't want a shareholder lawsuit if things go poorly with the FDA.
  Forum: By Share Code

scipio79
Posted on: May 2 2019, 06:10 AM


Group: Member
Posts: 77

Joined the final buy-in club yesterday and today. GLTA
  Forum: By Share Code

scipio79
Posted on: Apr 27 2019, 09:37 AM


Group: Member
Posts: 77

When I was 19 in 1998, I bought Amazon stock. My microeconomics professor and stock trading mentor said I was crazy because the price was ridiculous. I only wish i still owned the stock today. Clinuvel stock will pop. The only question is when.
  Forum: By Share Code

scipio79
Posted on: Apr 25 2019, 01:12 AM


Group: Member
Posts: 77

I am not saying Clinuvel can't control it's own product, merely the FDA can't limit a doctor's professional judgment. I expect Clinuvel to limit itself, at least in the short term.
  Forum: By Share Code

scipio79
Posted on: Apr 24 2019, 07:52 PM


Group: Member
Posts: 77

I am not sure the US First Amendment would allow such a restriction on commercial speech of doctors. There may be approved uses that clinuvel will abide by in its marketing, but the doctor would have a right to prescribe however he/she deemed professionally effective. That said, this area of law is not within my practice.
  Forum: By Share Code

scipio79
Posted on: Apr 12 2019, 03:02 AM


Group: Member
Posts: 77

For the first time in nearly 20 years of using TDAmeritrade (formerly Ameritrade), the company's local agent called to "see how I was doing" and if I had "any issues" I needed assistance with. Interestingly, the conversation turned to Clinuvel and my knowledge of the company. I thought it was weird. I'm not sure if he called because of Clinuvel or because of my recent returns, but he was really curious about our diamond in the rough here.
  Forum: By Share Code

scipio79
Posted on: Feb 28 2019, 11:22 PM


Group: Member
Posts: 77

After 15 years, nice to see some real returns. I have shares in several accounts. It's particularly nice to see the account where the average purchase price was .79 (that's 8 cents pre reverse split) and the return of 2800%!!
  Forum: By Share Code

scipio79
Posted on: Jan 15 2019, 08:57 PM


Group: Member
Posts: 77

American doctors are free to prescribe a drug for any reason they deem fit. However, USA law requires marketing only for approved indications. I posted the law on this a year or two ago.

Found it: http://www.circare.org/fda/fdadrugbulletin_041982.pdf pg 4-5
  Forum: By Share Code

scipio79
Posted on: Jan 15 2019, 10:49 AM


Group: Member
Posts: 77

There’s currently three Exchange Traded Funds (ETFs) that track the performance of the ASX 200 index:

BetaShares FTSE RAFI Australia 200 (QOZ)
iShares Core S&P/ASX 200 (IOZ)
SPDR S&P/ASX 200 (STW)

There’s currently one Exchange Traded Funds (ETF) that tracks the performance of the S&P/ASX 300: Vanguard Australian Shares Index (VAS)

Inclusion in the ASX 200 would mean a new buying spree.
  Forum: By Share Code

scipio79
Posted on: Jan 4 2019, 08:35 PM


Group: Member
Posts: 77

Yes. I made my final purchase as well. Good luck!
  Forum: By Share Code

scipio79
Posted on: Sep 30 2018, 09:15 AM


Group: Member
Posts: 77

https://pressreleases.responsesource.com/ne...s-demonstrates/
Could be a very promising stock.
  Forum: By Share Code

scipio79
Posted on: Sep 27 2018, 11:15 PM


Group: Member
Posts: 77

A couple of articles on future scenesse markets:
http://m.digitaljournal.com/pr/3955706
http://m.digitaljournal.com/pr/3954921

Oh, and I'll think of selling some shares at 100 USD. But I'm 39 and have time, God willing.
  Forum: By Share Code

scipio79
Posted on: Sep 23 2018, 03:03 AM


Group: Member
Posts: 77

Submitted. Thanks for writing a draft.
  Forum: By Share Code

scipio79
Posted on: Jul 6 2018, 04:32 AM


Group: Member
Posts: 77

www.fda.gov/downloads/drugs/newsevents/ucm580428.pdf

Almost two years old but I could not remember it being posted.
  Forum: By Share Code

scipio79
Posted on: Jun 23 2018, 12:02 AM


Group: Member
Posts: 77

I just purchased more! USA open for the swift of heart.
  Forum: By Share Code

scipio79
Posted on: May 13 2018, 01:08 AM


Group: Member
Posts: 77

11500 clvly
  Forum: By Share Code

scipio79
Posted on: Apr 26 2018, 07:09 AM


Group: Member
Posts: 77

Yep, Im a minor shareholder on this board at 11500 shares
  Forum: By Share Code

scipio79
Posted on: Nov 6 2017, 12:30 AM


Group: Member
Posts: 77

http://www.circare.org/fda/fdadrugbulletin_041982.pdf

See pg 4-5 where the FDA itself speaks about unlabeled uses of approved drugs.
  Forum: By Share Code

scipio79
Posted on: Jul 1 2017, 03:40 AM


Group: Member
Posts: 77

http://www.sciencedirect.com/science/artic...190962216310957

Scenesse is discussed in this article. Anybody have it?

Edit: nevermind, I see it below.
  Forum: By Share Code

scipio79
Posted on: Jun 17 2017, 08:41 AM


Group: Member
Posts: 77

http://www.evaluategroup.com/Universal/Vie...y&id=260056

One more google search and I discovered she is involved in the trials or at least phase I.
  Forum: By Share Code

scipio79
Posted on: Jun 17 2017, 08:38 AM


Group: Member
Posts: 77

http://practicaldermatology.com/2016/06/so...vitiligo-puzzle

A year old, but myth nine speaks to clinuvel and vitiligo. Dr. Grimes comments as well. We should also all pay attention to Dr. Grimes as I am fairly confident she will be involved in US clinical trials.
  Forum: By Share Code

scipio79
Posted on: May 23 2017, 06:55 AM


Group: Member
Posts: 77

https://www.fda.gov/downloads/drugs/newsevents/ucm530480.pdf

I could not remember if this had been posted previously. Do a search for scenesse in the pdf. Great anecdotal evidence from actual patients that were distraught when the trial ended.
  Forum: By Share Code

scipio79
Posted on: May 21 2017, 02:03 AM


Group: Member
Posts: 77

FDA approval of a drug with the side effect of a tan = $20 per share?! Not a chance. Only if the FDA imposes prescription restrictions. Even if it does, there will be a huge growth of EPP sufferers in the US all the sudden wink.gif
  Forum: By Share Code

scipio79
Posted on: Oct 12 2016, 02:08 AM


Group: Member
Posts: 77

9.45
  Forum: By Share Code

scipio79
Posted on: May 11 2016, 01:51 PM


Group: Member
Posts: 77

Heck, I plan on being a millionaire with my just over 10k shares!
  Forum: By Share Code

scipio79
Posted on: Apr 27 2016, 05:10 AM


Group: Member
Posts: 77

I really hope the news is as great as expected. When Scenesse got EMA approval, I remember the share price didn't really pop as the price had already run up. Let's hope we are not disappointed in a similar manner if we get good news this week.
  Forum: By Share Code

scipio79
Posted on: Apr 12 2016, 07:33 AM


Group: Member
Posts: 77

Fair point royco. Relative to my 10000 shares, it's significant daily purchasing; but in the big scheme of 47 million outstanding shares, its not much. However, in terms of daily volume, its a good amount.
  Forum: By Share Code

scipio79
Posted on: Apr 12 2016, 02:42 AM


Group: Member
Posts: 77

http://www.asx.com.au/asxpdf/20160411/pdf/436fg7v0dtxdll.pdf

Lagoda is buying significant amounts of shares in the $4 dollar range. They must think this thing is going to take off.
  Forum: By Share Code

scipio79
Posted on: Apr 8 2016, 01:38 AM


Group: Member
Posts: 77

If my math is correct, that's a share price of 8.50 with a 20 PE.
  Forum: By Share Code

scipio79
Posted on: Apr 4 2016, 12:40 PM


Group: Member
Posts: 77

70 million estimated worldwide have vitiligo according to the video. If scenesse can reach just 1% at 10000 US dollars per year, well do the math. 7 billion. We are sitting on a diamond mine gentlemen.
  Forum: By Share Code

scipio79
Posted on: Apr 4 2016, 09:01 AM


Group: Member
Posts: 77

http://www.umassmed.edu/vitiligo/blog/blog...ope-and-change/

Watch the video. Vitiligo=$$$
  Forum: By Share Code

scipio79
Posted on: Apr 4 2016, 08:52 AM


Group: Member
Posts: 77

http://www.umassmed.edu/vitiligo/blog/blog...d-in-singapore/

Interesting Univ. of Mass. blog post from January.
  Forum: By Share Code

scipio79
Posted on: Apr 2 2016, 09:14 AM


Group: Member
Posts: 77

http://www.fool.com/investing/general/2016...-in-eczema.aspx

Two points from this article:
1) Humira treatment , an immunosuppressant, costs $60000 US dollars per year. Scenesse is a bargain at 15000 euros per year.

2) Successful stage 3 trials to treat atopic dermatitis caused regeneron to take off. Been invested in clinuvel for a decade. Half a regeneron like price would be nice, even if 5 to ten years away.
  Forum: By Share Code

scipio79
Posted on: Apr 2 2016, 06:20 AM


Group: Member
Posts: 77

http://www.thestreet.com/story/13516015/1/...ug-results.html

The future?
  Forum: By Share Code

scipio79
Posted on: Mar 16 2016, 12:23 PM


Group: Member
Posts: 77

Let them sell. I'll buy more tomorrow.
  Forum: By Share Code


Cant find what you are looking for? Show all active topics from the last 3 months


New Posts  New Replies
No New Posts  No New Replies
Hot topic  Hot Topic (New)
No new  Hot Topic (No New)



TERMS OF USE  -  CONTACT ADMIN  -  ADVERTISING